Skip to content

Gross Profit at other companies

Pfizer logo
PfizerPFE
$10.9B+0.3%
Cardinal Health logo
Cardinal HealthCAH
$2.5B+17.7%
McKesson logo
McKessonMCK
$4.04B+11.1%
Cencora logo
CencoraCOR
$3.59B+17.3%
AbbVie logo
AbbVieABBV
$10.78B+15.4%
Viatris logo
ViatrisVTRS
$1.16B-0.3%

Segments

By segment

See full
Affordable Medicines$150.79M-15.3%
Specialty$90.25M+63.4%
AvKARE$39.08M+36.6%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s gross profit?
Amneal Pharmaceuticals, Inc. (AMRX) reported gross profit of $320.11M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s gross profit changed year-over-year?
Amneal Pharmaceuticals, Inc.'s gross profit increased by 25.1% year-over-year, from $255.89M to $320.11M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s gross profit?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s gross profit has grown at a 9.7% compound annual growth rate (CAGR), from $768.97M to $1.11B.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.